19T Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, and Canada. More details

19T fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Revenue is forecast to grow 35.32% per year

Risk Analysis

Has less than 1 year of cash runway

Shares are highly illiquid

Negative shareholders equity

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Idorsia Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for Idorsia
Historical stock prices
Current Share Price	CHF 1.59
52 Week High	CHF 1.59
52 Week Low	CHF 1.35
Beta	1.59
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-88.21%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	19T	DE Biotechs	DE Market
7D	14.0%	-1.4%	-0.9%
1Y	n/a	-12.5%	14.1%

Return vs Industry: Insufficient data to determine how 19T performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 19T performed against the German Market.

Price Volatility

Is 19T's price volatile compared to industry and market?
19T volatility
19T Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.4%
Market Average Movement	6.5%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 19T's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 19T's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	n/a	Andre Muller	www.idorsia.com

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia.

Idorsia Ltd Fundamentals Summary

How do Idorsia's earnings and revenue compare to its market cap?
19T fundamental statistics
Market cap	€338.77m
Earnings (TTM)	-€247.20m
Revenue (TTM)	€173.02m

2.0x

P/S Ratio

-1.4x

P/E Ratio

Is 19T overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
19T income statement (TTM)
Revenue	CHF 161.33m
Cost of Revenue	CHF 173.15m
Gross Profit	-CHF 11.81m
Other Expenses	CHF 218.69m
Earnings	-CHF 230.50m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Jul 30, 2025

Earnings per share (EPS)	-1.13
Gross Margin	-7.32%
Net Profit Margin	-142.87%
Debt/Equity Ratio	-100.0%

How did 19T perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/25 12:08
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Idorsia Ltd is covered by 12 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Maria Maldonado	Bank Vontobel AG
Jean-Philippe Bertschy	Bank Vontobel AG
Rosie Turner	Barclays